Affiliation:
1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria , Alexandria , Egypt
2. Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Damanhour University , Beheira , Egypt
Abstract
Abstract
The widespread coronavirus 2019 (COVID-19) pandemic, attributed to the severe acute respiratory syndrome coronavirus-2, has resulted in global lockdowns and excess mortality. Remdesivir (RM) is the first and only antiviral drug that the US Food and Drug Administration (FDA) has approved so far for COVID-19. The treatment protocol involves multidrug combinations, basically depending on RM, in addition to antimicrobials, antipyretics, corticosteroids, and anticoagulants. This study develops and validates sensitive and selective RM screening in spiked human plasma in the presence of commonly co-administered drugs. Hydroxychloroquine, azithromycin, paracetamol, dexamethasone, and anticoagulants (rivaroxaban and edoxaban) have been detected simultaneously with RM in the same biological matrix. Separation has been efficiently achieved by simple reversed phase HPLC with dual detectors. Diode array detector and fluorimetric detection have been used to compare their sensitivity and selectivity. Both assays have been validated according to bioanalytical FDA validation parameters. Chromatographic separation and quantitation of RM along with concomitant drugs instantly bioscreen COVID-19 multiple therapy medication in 10 min run time. Furthermore, the proposed in vitro study takes the lead for prospective testing of possible drug–drug interactions that alter the pharmacokinetic profiles of drugs.
Reference23 articles.
1. Bergman SJ, Cennimo D, Miller M, Olsen K Treatment of coronavirus disease 2019 (COVID-19): investigational drugs and other therapies. Medscape diunduh dari; 2020. https://emedicinemedscape.com/article/2500116-overview. (accessed 22 February 2021).
2. Magro G. COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res. 2020;286:198070. 10.1016%2Fj.virusres.2020.198070.
3. Venkatasubbaiah M, Reddy PD, Satyanarayana SV. Literature-based review of the drugs used for the treatment of COVID-19. Curr Med Res Pract. 2020;10(3):100–9. 10.1016%2Fj.cmrp.2020.05.013.
4. Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. J Clin Immunol. 2020;215:108409. 10.1016/j.clim.2020.108409.
5. Al-Tannak NF, Novotny L, Alhunayan A. Remdesivir—bringing hope for COVID-19 treatment. Sci Pharm. 2020;88(2):29. 10.3390/scipharm88020029.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献